<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive drugs. There is a linear relationship between blood pressure levels and the risk of complications (myocardial infarction, stroke, chronic heart and renal failure). Angiotensin receptor blockers are the first-line drugs for initial therapy of uncomplicated hypertension. Irbesartan is one of the most studied angiotensin receptor blockers. Data supporting the high antihypertensive and nephroprotection efficacy of irbesartan as well as its ability to reduce cardiovascular risk in hypertensive patients are presented.</p
<em>A prolonged open non comparative study of efficacy and safety of various doses of specific angio...
BACKGROUND: The risk of cardiovascular events among patients with atrial fibrillation is high. We ev...
Blockade of the renin-angiotensin system is recognized as an effective approach for the treatment of...
none2noIrbesartan is an orally active angiotensin II type 1 receptor antagonist (angiotensin recepto...
Although an impressive array of efficacious antihypertensive agents are available to treat hypertens...
Valentina Forni, Gr&eacute;goire Wuerzner, Menno Pruijm, Michel BurnierService of Nephrology and...
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficac...
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1...
Blood pressure is one of the most important and frequent risk factors for cardiovascular disease mor...
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often po...
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied ...
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of ...
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetiti...
The angiotensin-receptor blockers (ARBs) are approvedby the Food and Drug Administration for treatme...
PubMedID: 16029995Objectives. This multicenter, three-armed, opened-labelde study investigated patie...
<em>A prolonged open non comparative study of efficacy and safety of various doses of specific angio...
BACKGROUND: The risk of cardiovascular events among patients with atrial fibrillation is high. We ev...
Blockade of the renin-angiotensin system is recognized as an effective approach for the treatment of...
none2noIrbesartan is an orally active angiotensin II type 1 receptor antagonist (angiotensin recepto...
Although an impressive array of efficacious antihypertensive agents are available to treat hypertens...
Valentina Forni, Gr&eacute;goire Wuerzner, Menno Pruijm, Michel BurnierService of Nephrology and...
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficac...
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1...
Blood pressure is one of the most important and frequent risk factors for cardiovascular disease mor...
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often po...
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied ...
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of ...
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetiti...
The angiotensin-receptor blockers (ARBs) are approvedby the Food and Drug Administration for treatme...
PubMedID: 16029995Objectives. This multicenter, three-armed, opened-labelde study investigated patie...
<em>A prolonged open non comparative study of efficacy and safety of various doses of specific angio...
BACKGROUND: The risk of cardiovascular events among patients with atrial fibrillation is high. We ev...
Blockade of the renin-angiotensin system is recognized as an effective approach for the treatment of...